Remove 2027 Remove Leads Remove Patients
article thumbnail

Akili digital therapeutic shows promise in lupus patients

pharmaphorum

Akili looks like it could bring another digital therapeutic (DTx) to market after a clinical trial backed the efficacy of its AKL-T01 in patients with the autoimmune disorder systemic lupus erythematosus (SLE). The post Akili digital therapeutic shows promise in lupus patients appeared first on.

Patients 129
article thumbnail

CD19 CAR-T agents to boost blood cancer market

European Pharmaceutical Review

The number of blood cancer patients receiving CD19-directed CAR-T therapies is set to boom over the next decade from approximately 3,700 patients in 2021 to nearly 13,500 patients in 2031. It is set to retain its market-leading position as the most lucrative CD19 CAR-T agent in NHL, with annual sales reaching $1.7

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Transforming oncology with antibody therapeutics

European Pharmaceutical Review

Data announced at the European Lung Cancer Congress (ELCC) earlier this month revealed the long-term efficacy and safety of RYBREVANT ® (amivantamab) in patients with post-platinum EGFR Ex20ins-mutated advanced non-small cell lung cancer (NSCLC). 3 , 4 There is a high unmet need for novel and targeted therapies for this patient population.

article thumbnail

Why is microbiological testing in medical device manufacturing important?

European Pharmaceutical Review

Importantly, they identify potential sources of microbial contamination and assess their risk to patients. This microbial contamination can lead to a range of adverse events, such as infections, adverse reactions, or device failures, which can compromise patient safety and health outcomes. Sharma et al.

article thumbnail

European PFAS restriction could jeopardise pharmaceutical manufacturing

European Pharmaceutical Review

EMA prepares for winter antibiotic shortages PFAS restriction in pharmaceutical manufacturing In its current form, the procedure currently underway could lead to a ban on all PFASs by 2027, with very limited derogations, EFPIA acknowledged. The organisation’s response included results from a patient impact analysis.

article thumbnail

Consequences of the First 10 Drugs Selected for Medicare’s Negotiation Program

PM360

This article covers some of the reasons these drugs were chosen, how the process for price negotiation will occur, and the impact for the industry and for patients. Over the next few weeks, manufacturers will submit a range of clinical, marketing, sales, pricing, and patient data, and then meet with CMS to discuss submissions later this fall.

article thumbnail

Nine for 2023, part two: healthcare’s hard problem, the prognosis for diagnosis, and key new pharmacotherapy platforms

pharmaphorum

Even where there has been innovation, for example in cholesterol lowering with PCSK-9s and the siRNA treatment Leqvio, the vast majority of patients are on generic versions of medicines launched in the 1990s, and innovative medicines have not transformed the treatment paradigm. Innovation will power the market.

FDA 98